For biotech companies developing an immuno-oncology (IO) therapy, the complexity of oncology clinical trials takes on new dimensions, shaped by the advancement in translational science, new therapeutic platforms, unique mechanisms of action, novel trial designs and more. Add on to that, a dynamic IO clinical trial space that has grown exponentially in Japan-Asia Pacific (JAPAC) as the region brings benefits such as streamlined development and optimized costs for emerging to established biotech companies.

However, even most seasoned biotech executives face unique challenges in managing complex IO clinical trial challenges. To overcome these, biotechs must assess and consider leveraging a CRO partner with wide IO knowledge as well as experience with the nuances of the regulatory environment, medical research and infrastructures, and accessing patient populations, to conduct IO trials with efficiency, consistency and speed.

This white paper reviews the current IO landscape and considerations for biotech companies preparing for IO studies, and examines JAPAC's benefits as a location for clinical development to help bring enhanced IO therapies to market. Download to find out more.